Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate PFE stock a Sell.

In terms of liquidity and interest, the mean open interest for Pfizer options trades today is 13596.29 with a total volume of 13,024.00. In the following chart, we are able to follow the development ...

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Pfizer ($PFE) may finally be turning the corner on its post-pandemic revenue challenges. The company recently reported breakthrough survival data ...

Pfizer's (NYSE:PFE) stock is up by a considerable 10% over the past three months. We wonder if and what role the company's financials play in that price change as a company's long-term fundamentals ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Dividend stocks are a time-tested way to retire or protect your portfolio if you are already retired. Their yield can give ...

Returns for PFE stock were 67% in 2021, -10% in 2022, and -41% in 2023. In contrast, the Trefis High Quality Portfolio, with a collection of 30 stocks, is considerably less volatile.

A few weeks back, we discussed that Pfizer’s (NYSE: PFE) stock price could rebound over a one-month period after falling 4% in a week, based on its historical performance. However, PFE stock has ...